Merck, Hansoh Pharma Enter Exclusive Global License Agreement For HS-10535, An Investigational Preclinical Oral Small Molecule GLP-1 Receptor Agonist; Hansoh To Receive An Upfront Payment Of $112M And Up To $1.9B In Milestones
Merck, Hansoh Pharma Enter Exclusive Global License Agreement For HS-10535, An Investigational Preclinical Oral Small Molecule GLP-1 Receptor Agonist; Hansoh To Receive An Upfront Payment Of $112M And Up To $1.9B In Milestones
Under the agreement, Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535. Hansoh Pharma will receive an upfront payment of $112 million and is eligible to receive up to $1.9 billion in milestone payments associated with the development, regulatory approval and commercialization of the candidate, as well as royalties on sales.
根據協議，翰森製藥已向默沙東授予獨家全球許可，以開發、生產和商業化HS-10535。翰森製藥將獲得11200萬美元的預付款，並有資格獲得與候選藥物開發、監管批准和商業化相關的高達19億的里程碑付款，以及銷售的版稅。
Hansoh Pharma may co-promote or solely commercialize HS-10535 in China subject to certain conditions. Merck will record a pre-tax charge of $112 million, or $0.04 per share, to be included in GAAP and non-GAAP results in the fourth quarter of 2024.
翰森製藥可以在中國共同推廣或單獨商業化HS-10535，但需遵循某些條件。默沙東將在2024年第四季度錄入11200萬美元的稅前費用，或每股0.04美元，這將包含在GAAP與非GAAP結果中。
譯文內容由第三人軟體翻譯。
